⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 4, 2025Open Access

Supplementary Figure S8 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors

Min Wang Yanxing Chen Lin Tian Chenyi Wu Jiaying Chen Jiajia Hu Runjie Huang Yingnan Wang Jinling Zhang Xiaojun Ouyang Liqin Wang Ying Jin Qi Zhao Feng Wang Rui‐Hua Xu

View Full Paper

Ask AI

Bookmark

Share

Key Points

The integration of vascular normalization significantly boosts antitumor efficacy with immunotherapy.
Chidamide combined with anti-VEGFR-2 antibody enhances therapeutic effects in various solid tumors.
This approach centers on improving immune responses in cancer treatment with innovative strategies.
These findings may lead to new treatment options for patients with solid tumors facing resistance.

Implication

Combined chidamide and anti-VEGFR-2 antibody improves treatment outcomes in solid tumors, suggesting enhanced immunotherapy efficacy.

Abstract

ombined chidamide with anti-VEGFR-2 antibody facilitates the immunotherapy efficacy in multiple solid tumors

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68c18c089b7b07f3a06148dc https://doi.org/10.1158/2159-8290.30050790

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S3 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
2Supplementary Figure S6 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
3Supplementary Figure S9 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
4Supplementary Figure S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
5Supplementary Figure S1 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025

More related papers

Supplementary Figure S7 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
Supplementary Figure S5 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
Supplementary Figure S4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025